All Stories

  1. A Young Woman with Paraneoplastic Cushing’s Syndrome Due to a Pulmonary Carcinoid
  2. Hypersomatotropism and Hypercortisolism Caused by a Plurihormonal Pituitary Adenoma in a Dog
  3. Experience evolves into evidence in the new MEN1 guidelines
  4. High prevalence of deleterious germline variants in cancer risk genes among subjects with young-onset, sporadic pituitary macroadenomas
  5. Tatton-Brown-Rahman syndrome: A new multiple endocrine neoplasia syndrome with intellectual disability?
  6. Expanding the phenotype of multiple endocrine neoplasia type 5 (MEN5): Pituitary gigantism, myelolipoma and familial pheochromocytoma due to a germline pathogenic MAX variant
  7. SIADH as an uncommon presentation of olfactory neuroblastoma: a case-based overview
  8. Chromatin conformation capture in the clinic: 4C-seq/HiC distinguishes pathogenic from neutral duplications at the GPR101 locus
  9. The Genetic Pathophysiology and Clinical Management of the TADopathy, X-Linked Acrogigantism
  10. Pituitary Acrogigantism: From the Past to the Future
  11. The Role of MCM9 in the Etiology of Sertoli Cell-Only Syndrome and Premature Ovarian Insufficiency
  12. Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion
  13. Bases moléculaires du gigantisme hypophysaire
  14. Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases
  15. Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor–Interacting Protein–mutated Pediatric Somatotropinoma
  16. Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism
  17. Comment on "Persistent remission of acromegaly in a patient with GH‐secreting pituitary adenoma: Effect of treatment with pasireotide long‐acting release and consequence of treatment withdrawal"
  18. Dutch founder SDHB exon 3 deletion in patients with pheochromocytoma-paraganglioma in South Africa
  19. Genetics of Pituitary Adenoma Syndromes
  20. A hard look at cardiac safety with dopamine agonists in endocrinology
  21. Differentiated thyroid carcinoma in sporadic and familial presentations of acromegaly: A case series
  22. GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11
  23. miR ‐34a is upregulated in AIP ‐ mutated somatotropinomas and promotes octreotide resistance
  24. The Epidemiology of Pituitary Adenomas
  25. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis
  26. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA)
  27. Pituitary Disease in AIP Mutation-Positive Familial Isolated Pituitary Adenoma (FIPA): A Kindred-Based Overview
  28. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
  29. Pancreatic Neuroendocrine Neoplasm Associated with a Familial MAX Deletion
  30. The role of AIP variants in pituitary adenomas and concomitant thyroid carcinomas in the Netherlands: a nationwide pathology registry (PALGA) study
  31. Clinical and Molecular Update on Genetic Causes of Pituitary Adenomas
  32. Acromegaly in the setting of Tatton-Brown-Rahman Syndrome
  33. Long-term remission of disseminated parathyroid cancer following immunotherapy
  34. GENETICS IN ENDOCRINOLOGY: Somatic and germline mutations in the pathogenesis of pituitary adenomas
  35. Compound heterozygous mutations in the luteinizing hormone receptor signal peptide causing 46,XY disorder of sex development
  36. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma
  37. Shrinkage of pituitary adenomas with pasireotide
  38. AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center
  39. AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
  40. Epidemiology and Management Challenges in Prolactinomas
  41. Genetic Testing in Pituitary Adenomas: What, How, and In Whom?
  42. The causes and consequences of pituitary gigantism
  43. Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant
  44. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors
  45. MAX intragenic deletions occur in patients with pheochromocytoma and pituitary adenoma
  46. Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats
  47. Acromegaly characteristics at diagnosis: the largest study to date.
  48. Adipsic diabetes insipidus revealing a bifocal intracranial germinoma
  49. AIP mutations and gigantism
  50. Overview of XLAG and how we discovered it
  51. Transdifferentiation of Neuroendocrine Cells
  52. Elucidating the molecular mechanisms underlying AIP dependent tumorigenesis
  53. GPR101 orphan receptor: a novel cause of growth hormone deregulation
  54. Comment on “Hypogonadotrophic hypogonadism due to a mutation in the luteinizing hormone β-subunit gene”
  55. Primary hypertrophic osteoarthropathy due to a novel SLCO2A1 mutation masquerading as acromegaly
  56. A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues
  57. New technology combined with a new disease used to explain an old case of gigantism
  58. Genetics of Pituitary Tumor Syndromes
  59. The role of AIP mutations in pituitary adenomas: 10 years on
  60. Erratum to: Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia
  61. Polymorphism or mutation? - The role of the R304Q missense AIP mutation in the predisposition to pituitary adenoma
  62. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia
  63. A region, common to all glycoprotein homones, essential for secretion
  64. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly
  65. Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening
  66. Characterization ofGPR101transcript structure and expression patterns
  67. Genetic predisposition to breast cancer occurring in a male-to-female transsexual patient
  68. Combined treatment with octreotide LAR and pegvisomant in patients with gigantism - acromegaly: clinical evaluation and genetic screening
  69. Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells
  70. MANAGEMENT OF ENDOCRINE DISEASE: Pituitary ‘incidentaloma’: neuroradiological assessment and differential diagnosis
  71. Genetic risk of breast cancer is important to consider in transexuals receiving hormone therapy
  72. Screening for GPR101 defects in pediatric pituitary corticotropinomas
  73. Mosaicism for X chromosome duplications including GPR101 cause X-LAG syndrome in sporadic males
  74. Gigantism, acromegaly and GPR101
  75. Bifocal intracranial germinoma presenting as adipsic diabetes insipidus
  76. Erratum to “Pituitary gigantism: Causes and clinical characteristics” [Ann. Endocrinol. (Paris) 76 (2015) 643–649]
  77. GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency
  78. Functioning Pituitary Adenomas
  79. List of Contributors
  80. Growth hormone releasing hormone is abnormally elevated in patients with X-linked acrogigantism
  81. Pituitary gigantism: Causes and clinical characteristics
  82. Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome
  83. Étude moléculaire du gène AIP sur plus de 1400 individus atteints d’adénome hypophysaire
  84. Hyperparathyroïdie primaire familiale isolée – corrélation génotype-phénotype des mutations MEN1 ?
  85. Une forme compliquée d’hypercalcémie hypocalciurique familiale
  86. Causes and Characteristics of Pituitary Gigantism
  87. Pancreatitis in familial hypocalciuric hypercalcaemia
  88. Molecular analysis of miRNA expression profiles in AIP mutation positive somatotropinomas
  89. Recurrence of GH-secreting pituitary adenomas during puberty in children with germline AIP mutations: a clinical challenge
  90. Molecular and pathological determinants of somatostatin analogue resistance: somatotropinomas in AIP mutated and X-LAG syndrome patients
  91. The genetic causes of pituitary gigantism
  92. The clinical characteristics of X-linked acro-gigantism syndrome
  93. X-linked acro-gigantism (X-LAG): a new form of infant-onset pituitary gigantism
  94. Gigantism, Acromegaly, and GPR101 Mutations
  95. A novel inactivating mutation of the LH/chorionic gonadotrophin receptor with impaired membrane trafficking leading to Leydig cell hypoplasia type 1
  96. Familial Isolated Pituitary Adenomas (FIPA) and Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene
  97. X-linked acrogigantism syndrome: clinical profile and therapeutic responses
  98. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences
  99. Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation
  100. McCune-Albright Syndrome: A Detailed Pathological and Genetic Analysis of Disease Effects in an Adult Patient
  101. Le cancer thyroïdien papillaire familial (FNMTC) : études cliniques et génétiques chez 8 familles
  102. Intérêt du signal T2 des adénomes hypophysaires à GH traités par analogues de la somatostatine – premiers résultats de l’étude IRMA#2
  103. Challenges and controversies in the treatment of prolactinomas
  104. A clinically novel AIP mutation in a patient with a very large, apparently sporadic somatotrope adenoma
  105. A bittersweet symphony
  106. Surgical management of pituitary adenomas
  107. The Third/Second Generation PTH Assay Ratio as a Marker for Parathyroid Carcinoma: Evaluation Using an Automated Platform
  108. Deletion of exons 1–3 of the MEN1 gene in a large Italian family causes the loss of menin expression
  109. Coexistence entre adénome hypophysaire et phéochromocytome – présentation de cas
  110. FIPA : étude clinique et génétique à l’Hôpital « King Edward Memorial », Bombay (Mumbai), Inde
  111. Le Gigantisme : les résultats d’une étude clinique et génétique internationale
  112. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations
  113. Faculty Opinions recommendation of Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma.
  114. Receptor expression in craniopharyngiomas causing tumor growth in pregnancy: case report and review of the literature
  115. Characteristics of patients with pituitary gigantism: results of an international study
  116. Familial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene
  117. Young patients with pituitary adenomas should be assessed for MEN1 and AIP mutations
  118. Familial Pituitary Adenomas: An Overview
  119. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients
  120. Faculty Opinions recommendation of Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues.
  121. Faculty Opinions recommendation of Should aip gene screening be recommended in family members of FIPA patients with R16H variant?
  122. A study of the characteristics of cabergoline-resistant prolactinomas
  123. The Liege Acromegaly Survey (LAS): A new software tool for the study of acromegaly
  124. Clinical and genetic aspects of familial isolated pituitary adenomas
  125. Faculty Opinions recommendation of The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression.
  126. Overview of genetic testing in patients with pituitary adenomas
  127. Clinical characterization of cabergoline resistant prolactinomas: A multicenter experience on 92 patients
  128. A prospective study of cardiac valvular status in patients treated with cabergoline for endocrine disease
  129. Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds
  130. Faculty Opinions recommendation of Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype.
  131. Faculty Opinions recommendation of Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain.
  132. 36. A Tall Man with Hypogonadism
  133. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas
  134. Familial Pituitary Tumor Syndromes
  135. What to do with a pituitary incidentaloma?
  136. A Novel AIP Mutation Related to Familial Isolated Pituitary Adenomas (FIPA)
  137. Strategies for Screening and Management of Familial Isolated Pituitary Adenomas (FIPA): Our Experience on 17 Families in a Single Center in Brazil
  138. Impact of Germline AIP Mutations on Tumor Characteristics and Management in Young Acromegalic Patients: Results of an Age- and Tumor-Diameter-Matched Cohort Study
  139. Mutations of calcium-sensing receptor gene: two novel mutations and overview of impact on calcium homeostasis
  140. Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation
  141. Resistant prolactinomas
  142. Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications
  143. Genetic Causes of Familial Pituitary Adenomas
  144. Familial pituitary adenomas
  145. Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene
  146. Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study
  147. The Ratio of Parathyroid Hormone as Measured by Third- and Second-Generation Assays as a Marker for Parathyroid Carcinoma
  148. Management of acromegaly
  149. The genetics of pituitary adenomas
  150. Hyperplasia-Adenoma Sequence in Pituitary Tumorigenesis Related to AIP Mutation.
  151. Prevalence of double pituitary adenomas in a surgical series: Clinical, histological and genetic features
  152. The role of germlineAIP,MEN1, PRKAR1A,CDKN1BandCDKN2Cmutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes
  153. Functioning Pituitary Adenomas
  154. Genetics of Cushing’s Syndrome
  155. Contributors
  156. Genetic Factors in the Development of Pituitary Adenomas
  157. Pituitary adenomas in young patients: when should we consider a genetic predisposition?
  158. The epidemiology and genetics of pituitary adenomas
  159. De la génétique des adénomes hypophysaires familiaux
  160. Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene
  161. Mutaciones de AIP en adenomas hipofisarios familiares y esporádicos: experiencia local y revisión de la literatura
  162. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly
  163. Familial pituitary adenomas
  164. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications
  165. Genetic, Molecular and Clinical Features of Familial Isolated Pituitary Adenomas
  166. Adénomes hypophysaires familiaux
  167. Update on Familial Pituitary Tumors: from Multiple Endocrine Neoplasia Type 1 to Familial Isolated Pituitary Adenoma
  168. Testicular Effects of Isolated Luteinizing Hormone Deficiency and Reversal by Long-Term Human Chorionic Gonadotropin Treatment
  169. Central Nervous System-Acting Drugs Influencing Hypothalamic-Pituitary-Adrenal Axis Function
  170. UPDATE ON THE TREATMENT OF PITUITARY ADENOMAS: FAMILIAL AND GENETIC CONSIDERATIONS
  171. Toll‐like receptor‐4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel
  172. Cabergoline and the risk of valvular lesions in endocrine disease.
  173. Absence of hypogonadism in a male patient with a giant prolactinoma: A clinical paradox
  174. Current and future perspectives on recombinant growth hormone for the treatment of obesity
  175. Pseudomalabsorption of thyroid hormones: case report and review of the literature
  176. Characteristics of familial isolated pituitary adenomas
  177. Vitex agnus castus might enrich the pharmacological armamentarium for medical treatment of prolactinoma
  178. The clinical, pathological, and genetic features of familial isolated pituitary adenomas
  179. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene
  180. Mutations in theAryl Hydrocarbon Receptor Interacting ProteinGene Are Not Highly Prevalent among Subjects with Sporadic Pituitary Adenomas
  181. Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families
  182. The Epidemiology and Management of Pituitary Incidentalomas
  183. High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
  184. P1-046 - The liege acromegaly survey
  185. CO05 - Identification d’une famille porteuse d’une nouvelle mutation bêta-LH accompagnée d’hypogonadisme
  186. P2-085 - Endocrine abnormalities in MC Cune-Albright syndrome
  187. P1-044 - Les patients acromégales sont-ils mal pris en charge ? de la mauvaise utilisation des bases de données
  188. The original clinical description of familial isolated pituitary adenomas (FIPA)
  189. Serum levels of soluble CD163 correlate with the inflammatory process in coeliac disease
  190. Desloratadine for allergic rhinitis
  191. Diagnostic characteristics and therapeutic responses in acromegaly: The liege acromegaly survey
  192. Does the nadir growth-hormone level predict response to somatostatin-analogue therapy?
  193. Somatostatin Analogs in the Gastrointestinal Tract
  194. Predictors and rates of treatment-resistant tumor growth in acromegaly
  195. Acromegaly
  196. Clinical and Genetic Features of Familial Pituitary Adenomas
  197. Treatment of Pituitary Tumors: Somatostatin
  198. The Epidemiology of Prolactinomas
  199. Cytokine Dysregulation, Inflammation and Well-Being
  200. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs
  201. Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique
  202. Hypogonadism in a Patient with a Mutation in the Luteinizing Hormone Beta-Subunit Gene
  203. P018 - Une approche de la vraie prévalence des tumeurs hypophysaires
  204. CO10 - La réduction chirurgicale de la masse tumorale des adenomas hypophysaires améliore le contrôle médical de l’acromégalie par les analogues de la somatostatine
  205. Oral vitamin C reduces the injury to skeletal muscle caused by compartment syndrome
  206. Hormonal and Biochemical Normalization and Tumor Shrinkage Induced by Anti-Parathyroid Hormone Immunotherapy in a Patient with Metastatic Parathyroid Carcinoma
  207. Lanreotide Autogel?? for Acromegaly
  208. Gonadotropin-Secreting Tumors
  209. Oral vitamin C attenuates acute ischaemia-reperfusion injury in skeletal muscle
  210. Alcoholic ketoacidosis presenting as diabetic ketoacidosis
  211. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines☆☆☆★
  212. Pathologie inflammatoire de ľhypophyse et grossesse